Referenciák

  1. Derosa G, D'Angelo A, Maffioli P. Sitagliptin in type 2 diabetes mellitus: efficacy after five years of therapy. Pharmacol Res 2015;100: 127–134
  2. Williams-Herman D et al. Diabetes, Obesity and Metabolism 2010;12(5):442–451
  3. Tatosian DA et al. Diabetes Ther. 2013;4:431–442
  4. Brazg R, Xu L, Dalla Man C, et al. Effect of adding sitagliptin, a dipeptidyl-peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabet Obes Metab. 2007;9:119–145
  5. Januvia alkalmazási előírás (EMA/2018. 01. 11.)
  6. Jardiance alkalmazási előírás (EMA/2017. 12. 08.)
  7. Aschner P et al. Diabetes Care 2006;29(12):2632–2637
  8. Kirpichnikov D et al. Ann Intern Med. 2002;137(1):25–33
  9. Abassi F et al. Diabetes Care 1998;21(8):1301–1305
  10. Musceli E et al. J Clin Endocrinol Metab 2012;97:2816–2826
  11. Engel SS et al Diabetes Ther. 2013;4(1):119–145
  12. Green JB et al. N Engl J Med. 2015;373(3);232–242
  13. Nakamura et al. Cardiovasc Diabetol (2016) 15:54 Cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12‑month follow‑up
  14. Giuseppe Derosa et al Fundham Clin Pharmacol 2014;28(2):222–229
  15. Janumet alkalmazási előírás (EMA/2018. 01. 11.)
  16. clinicaltrials.gov, 2016. 01. 12.
  17. Galvus alkalmazási előírás (EMA/2017. 05. 26.)
  18. IMS Health, 2016 március alapján
  19. IMS Health Monthly IMS External sales Final (Sept 2017)
  20. Rosta L.: Metabolizmus 2013. május XI. évfolyam 4. Supplementum D9–D12

Referenciák II.